Mitomycin Substipharm (Mitomycin)

Mitomycin is used in intravesical chemotherapy for urothelial malignancies.

• Bladder cancer (intravesical therapy): reduces recurrence and progression of superficial tumors.
• Upper urinary tract urothelial carcinoma: provides local cytotoxic effect to eradicate malignant cells.
• Recurrent superficial bladder tumors: helps prevent further tumor recurrence after transurethral resection.

• Mitomycin exerts its antineoplastic effect by forming covalent cross‑links between DNA strands, which blocks DNA synthesis and triggers apoptosis in rapidly dividing cancer cells. The drug is activated under low‑oxygen conditions typical of tumor microenvironments, enhancing its selective cytotoxicity toward malignant urothelial tissue.

Mitomycin may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects

• Bladder irritation: burning sensation during urination.
• Dysuria: painful or difficult urination.
• Hematuria: presence of blood in urine.
• Mild cystitis: inflammation of the bladder lining.
• Nausea: feeling of sickness or urge to vomit.
• Urinary frequency: need to urinate more often than usual.

Serious or Rare Side Effects

• Bone marrow suppression: leading to anemia, leukopenia, or thrombocytopenia.
• Renal toxicity: impaired kidney function or acute kidney injury.
• Severe allergic reaction: including anaphylaxis, rash, or swelling.
• Pulmonary fibrosis: scarring of lung tissue causing breathing difficulty.
• Life‑threatening infection: due to immunosuppression.

Before initiating Mitomycin therapy, several safety considerations should be observed.

• Monitor blood counts: regular CBC testing to detect bone marrow suppression.
• Assess renal function: check serum creatinine and eGFR prior to each dose.
• Avoid concurrent nephrotoxic drugs: limit use of aminoglycosides or high‑dose NSAIDs.
• Ensure proper catheter technique: maintain sterile conditions during intravesical administration.
• Counsel on infection signs: educate patients to report fever, chills, or unexplained bruising.
• Store at room temperature: keep in original container, protect from moisture and direct light.

Mitomycin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Concurrent use with other alkylating agents: may amplify bone marrow suppression.
• High‑dose radiation therapy: increases risk of severe tissue damage.

Moderate Interactions (Monitor Closely)

• Nephrotoxic antibiotics (e.g., aminoglycosides): monitor renal function closely.
• Anticoagulants (e.g., warfarin): watch for enhanced bleeding risk.
• NSAIDs: may worsen renal toxicity, require dose adjustment and renal monitoring.